APG Asset Management N.V. Cuts Stock Position in Axon Enterprise, Inc $AXON

APG Asset Management N.V. decreased its position in shares of Axon Enterprise, Inc (NASDAQ:AXON) by 9.4% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 43,400 shares of the biotechnology company’s stock after selling 4,518 shares during the period. APG Asset Management N.V. owned 0.05% of Axon Enterprise worth $31,146,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in AXON. Vanguard Group Inc. boosted its stake in Axon Enterprise by 4.2% in the 3rd quarter. Vanguard Group Inc. now owns 9,314,164 shares of the biotechnology company’s stock worth $6,684,217,000 after purchasing an additional 376,904 shares in the last quarter. Geode Capital Management LLC grew its holdings in Axon Enterprise by 5.9% during the second quarter. Geode Capital Management LLC now owns 2,072,186 shares of the biotechnology company’s stock worth $1,713,332,000 after acquiring an additional 115,349 shares during the period. Jennison Associates LLC increased its holdings in shares of Axon Enterprise by 53.8% during the 3rd quarter. Jennison Associates LLC now owns 943,944 shares of the biotechnology company’s stock valued at $677,412,000 after purchasing an additional 330,213 shares in the last quarter. Vestor Capital LLC increased its holdings in Axon Enterprise by 438,636.3% in the second quarter. Vestor Capital LLC now owns 833,599 shares of the biotechnology company’s stock valued at $690,170,000 after buying an additional 833,409 shares in the last quarter. Finally, Norges Bank acquired a new position in Axon Enterprise in the 2nd quarter worth about $637,806,000. Institutional investors and hedge funds own 79.08% of the company’s stock.

Insider Activity

In other news, CFO Brittany Bagley sold 2,000 shares of the company’s stock in a transaction on Thursday, December 11th. The shares were sold at an average price of $580.00, for a total value of $1,160,000.00. Following the sale, the chief financial officer directly owned 103,501 shares of the company’s stock, valued at approximately $60,030,580. This represents a 1.90% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, President Joshua Isner sold 20,000 shares of the company’s stock in a transaction on Monday, December 8th. The shares were sold at an average price of $552.60, for a total transaction of $11,052,000.00. Following the sale, the president directly owned 249,502 shares in the company, valued at $137,874,805.20. This trade represents a 7.42% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders sold 58,040 shares of company stock worth $32,251,738. 5.70% of the stock is owned by corporate insiders.

Axon Enterprise Stock Performance

Shares of Axon Enterprise stock opened at $542.40 on Monday. Axon Enterprise, Inc has a fifty-two week low of $396.41 and a fifty-two week high of $885.91. The company’s 50 day moving average price is $537.92 and its two-hundred day moving average price is $623.54. The company has a debt-to-equity ratio of 0.53, a current ratio of 2.53 and a quick ratio of 2.29. The firm has a market capitalization of $43.61 billion, a P/E ratio of 356.84, a P/E/G ratio of 12.23 and a beta of 1.46.

Axon Enterprise (NASDAQ:AXON) last announced its quarterly earnings results on Tuesday, February 24th. The biotechnology company reported $2.15 EPS for the quarter, beating analysts’ consensus estimates of $1.60 by $0.55. Axon Enterprise had a return on equity of 2.82% and a net margin of 4.48%.The firm had revenue of $796.72 million for the quarter, compared to analyst estimates of $755.29 million. During the same period last year, the firm posted $2.08 earnings per share. The business’s revenue for the quarter was up 38.5% on a year-over-year basis. On average, equities analysts forecast that Axon Enterprise, Inc will post 5.8 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on AXON shares. Citigroup restated a “buy” rating on shares of Axon Enterprise in a research report on Wednesday. Barclays lowered their price target on shares of Axon Enterprise from $702.00 to $682.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 25th. The Goldman Sachs Group decreased their price objective on Axon Enterprise from $940.00 to $800.00 and set a “buy” rating on the stock in a report on Wednesday, November 5th. Piper Sandler lowered their target price on shares of Axon Enterprise from $753.00 to $690.00 and set an “overweight” rating for the company in a research note on Wednesday, February 25th. Finally, TD Cowen restated a “buy” rating on shares of Axon Enterprise in a research report on Wednesday, November 5th. Sixteen investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, Axon Enterprise has an average rating of “Moderate Buy” and an average price target of $762.93.

Axon Enterprise News Roundup

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Q4 beat and bullish bookings — Axon reported a double beat (EPS and revenue), ~39% revenue growth and a material increase in future contracted bookings with raised multi‑year sales targets, which triggered the stock rally. Read More.
• Positive Sentiment: AI narrative driving subscription demand — Coverage highlights that Axon’s AI features (body‑camera analytics, Draft One report drafting, evidence management) are accelerating software adoption and upsells, supporting revenue visibility beyond hardware. Read More.
• Neutral Sentiment: Analysts recalibrating models — Several firms trimmed price targets after the print (Piper Sandler, others); many maintained buy/overweight stances, so these moves reflect model updates and volatility rather than a wholesale negative verdict. Read More.
• Neutral Sentiment: Short‑interest data flagged as anomalous — Recent short‑interest reports show zero/NaN figures (likely a reporting anomaly); nothing actionable from that data point for now.
• Negative Sentiment: Some analysts flag downside risk — Morgan Stanley and UBS issued more cautious outlooks/pessimistic scenarios that could cap upside if execution or margins slip. Read More. | Read More.
• Negative Sentiment: Profitability and margin recovery remain a watch item — Commentators note fast revenue growth but slower profit improvement and the need for FCF conversion; sustained margin progress is required to justify high multiples. Read More.
• Negative Sentiment: Insider sale disclosed — CEO Patrick Smith sold 10,000 shares (~$5.0M) on Feb. 25; small relative to his holdings but notable to traders monitoring insider activity. Read More.

Axon Enterprise Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.